| Scott Peterson, DO | |
|
3777 Coon Rapids Blvd Nw Ste 100, Coon Rapids, MN 55433-2630 | |
| (763) 421-7420 | |
| (763) 421-0730 |
| Full Name | Scott Peterson |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 12 Years |
| Location | 3777 Coon Rapids Blvd Nw Ste 100, Coon Rapids, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598121808 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 5101019986 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Edina Eye Physicians And Surgeons Pa | 1355382698 | 23 |
| St. Croix Regional Medical Center | 9335032184 | 164 |
| St. Croix Regional Medical Center | 9335032184 | 164 |
News Archive
SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France.
The International Association for the Study of Lung Cancer (IASLC) will hold an expert roundtable and Web cast announcing the recent publication and impact of the IASLC's Staging Manual in Thoracic Oncology containing the recently released 7th Edition of TNM in Lung and Pleural Tumours.
Despite progress in understanding the genetics of rare childhood epilepsies, the common adult forms of epilepsy have proven less amenable to traditional gene-discovery analyses.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
› Verified 1 days ago
| Entity Name | Edina Eye Physicians And Surgeons Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538264981 PECOS PAC ID: 1355382698 Enrollment ID: O20050518000059 |
News Archive
SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France.
The International Association for the Study of Lung Cancer (IASLC) will hold an expert roundtable and Web cast announcing the recent publication and impact of the IASLC's Staging Manual in Thoracic Oncology containing the recently released 7th Edition of TNM in Lung and Pleural Tumours.
Despite progress in understanding the genetics of rare childhood epilepsies, the common adult forms of epilepsy have proven less amenable to traditional gene-discovery analyses.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
› Verified 1 days ago
| Entity Name | St. Croix Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043240922 PECOS PAC ID: 9335032184 Enrollment ID: O20110929000165 |
News Archive
SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France.
The International Association for the Study of Lung Cancer (IASLC) will hold an expert roundtable and Web cast announcing the recent publication and impact of the IASLC's Staging Manual in Thoracic Oncology containing the recently released 7th Edition of TNM in Lung and Pleural Tumours.
Despite progress in understanding the genetics of rare childhood epilepsies, the common adult forms of epilepsy have proven less amenable to traditional gene-discovery analyses.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott Peterson, DO 3777 Coon Rapids Blvd Nw Ste 100, Coon Rapids, MN 55433-2630 Ph: () - | Scott Peterson, DO 3777 Coon Rapids Blvd Nw Ste 100, Coon Rapids, MN 55433-2630 Ph: (763) 421-7420 |
News Archive
SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France.
The International Association for the Study of Lung Cancer (IASLC) will hold an expert roundtable and Web cast announcing the recent publication and impact of the IASLC's Staging Manual in Thoracic Oncology containing the recently released 7th Edition of TNM in Lung and Pleural Tumours.
Despite progress in understanding the genetics of rare childhood epilepsies, the common adult forms of epilepsy have proven less amenable to traditional gene-discovery analyses.
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.
› Verified 1 days ago
Dr. James Adair Cameron, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3777 Coon Rapids Blvd Nw, Suite 100, Coon Rapids, MN 55433 Phone: 763-421-7420 Fax: 763-421-0730 | |
Dr. George Randall Wandling Jr., MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3777 Coon Rapids Blvd Nw # 100, Coon Rapids, MN 55433 Phone: 763-421-7420 | |
Dr. Matthew Sander Johnson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3777 Coon Rapids Blvd Nw, Suite 100, Coon Rapids, MN 55433 Phone: 763-421-7420 Fax: 763-592-8453 | |
Dr. Alfred Oscar Steldt, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3790 Coon Rapids Blvd Nw, Coon Rapids, MN 55433 Phone: 763-421-7420 Fax: 763-421-0730 | |
Dr. Patrick Kelly Johnson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3790 Coon Rapids Blvd Nw, Coon Rapids, MN 55433 Phone: 763-421-7420 Fax: 763-421-0730 | |
Dr. David V Folden, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3777 Coon Rapids Blvd Nw, Suite 100, Coon Rapids, MN 55433 Phone: 763-421-7420 Fax: 763-421-0730 |